Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor
cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
nelfinavir mesylate together with radiation therapy and temozolomide may kill more tumor
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir mesylate
when given together with radiation therapy and temozolomide in treating patients with
glioblastoma multiforme.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania